MarketCapExport financials
BioNano Genomics (BNGO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
BioNano Genomics Balance Sheet 2025-2011 | BNGO
Brief overview of BioNano Genomics's balance sheet structure
This overview follows the five latest available annual observations between 2021 and 2025.
Assets declined from $377.1 million to $73.6 million, or -80.5%. The contraction calls for context such as disposals, restructuring or weaker operations.
Liability growth of -27.1% exceeded asset growth of -80.5%, increasing reliance on outside funding.
Equity funds 60.4% of assets versus 89.4% initially. This creates a conservative balance sheet structure.
Each unit of equity supports about 0.03x of net debt. Dependence on debt remains comfortable.
Cash accounts for 4.1% of assets versus 6.5% initially. The change indicates the degree of financial flexibility.
Retained earnings are negative at -$719.6 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Overall picture
BioNano Genomics's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet BioNano Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
1.19 M | -2.64 M | -12.2 M | 788 K | -19.5 M | -2.04 M | 2.77 M | -7.49 M | 5.71 M | 1.38 M | - | - | - | - | - |
Long Term Debt |
3.48 M | 3.54 M | 3.58 M | 3.62 M | 3.64 M | 16.3 M | - | 9.03 M | - | 6.05 M | - | - | - | - | - |
Long Term Debt Current |
697 K | 2.99 M | 2.16 M | 2.26 M | 1.47 M | - | 20.1 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 16.4 M | 227 K | 10.1 M | 43.7 M | 32.7 M | - | - | - | - | - |
Total Current Liabilities |
22.9 M | 37.3 M | 100 M | 35.9 M | 21.8 M | 8.94 M | 26.4 M | 4.52 M | - | - | - | - | - | - | - |
Total Liabilities |
29.2 M | 41.3 M | 118 M | 58.1 M | 40 M | 25.4 M | 26.6 M | 14.7 M | 60.4 M | 42 M | - | - | - | - | - |
Deferred Revenue |
967 K | 1.13 M | 783 K | 871 K | 684 K | 416 K | 357 K | 271 K | 212 K | 447 K | - | - | - | - | - |
Retained Earnings |
-720 M | -693 M | -581 M | -349 M | -216 M | -144 M | -103 M | -72.8 M | -54.3 M | -30.9 M | - | - | - | - | - |
Total Assets |
73.6 M | 76.7 M | 214 M | 308 M | 377 M | 60.4 M | 30.2 M | 24.8 M | 10.1 M | 14.8 M | - | - | - | - | - |
Cash and Cash Equivalents |
2.99 M | 9.17 M | 17.9 M | 5.09 M | 24.6 M | 38.4 M | 17.3 M | 16.5 M | - | - | - | - | - | - | - |
Book Value |
44.4 M | 35.4 M | 96.2 M | 249 M | 337 M | 35.1 M | 3.61 M | 10.1 M | -50.2 M | -27.3 M | - | - | - | - | - |
Total Shareholders Equity |
44.4 M | 35.4 M | 96.2 M | 249 M | 337 M | 35.1 M | 3.61 M | 10.1 M | -50.2 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet BioNano Genomics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.49 M | 3.46 M | 145 K | 3.5 M | 3.51 M | 3.53 M | 3.54 M | 3.55 M | 3.56 M | 3.58 M | 3.58 M | 3.6 M | 3.6 M | 3.61 M | 3.62 M | 3.63 M | - | 3.64 M | 3.64 M | - | - | 14.9 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | - | - | - | 18.4 M | 9.03 M | 9.03 M | 9.03 M | 9.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
29.2 M | 27.3 M | 41.3 M | 29.3 M | 30.6 M | 30.2 M | 41.3 M | 38.5 M | 49 M | 75.2 M | 118 M | 62.9 M | 56.6 M | 60.7 M | 58.1 M | 42 M | - | 37 M | 40 M | 18.1 M | 10.9 M | 22.1 M | 25.4 M | 25.4 M | 25.4 M | 25.4 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 17.4 M | 17.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
967 K | 1.13 M | 1.13 M | 1.18 M | 1.16 M | 1.02 M | 1.13 M | 1.2 M | 1.15 M | 1.04 M | 783 K | 811 K | 978 K | 1.13 M | 871 K | 976 K | - | 1.11 M | 684 K | 411 K | 445 K | 301 K | 416 K | 412 K | 416 K | 416 K | 357 K | 418 K | 358 K | 214 K | 271 K | 336 K | 271 K | 271 K | 212 K | 212 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-720 M | -728 M | -693 M | -712 M | -703 M | -696 M | -693 M | -673 M | -629 M | -613 M | -581 M | -537 M | -425 M | -386 M | -349 M | -310 M | - | -246 M | -216 M | -193 M | -172 M | -154 M | -144 M | -144 M | -144 M | -144 M | -103 M | -103 M | -103 M | -103 M | -72.8 M | -72.8 M | -72.8 M | -72.8 M | -54.3 M | -54.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
73.6 M | 64.8 M | 76.7 M | 79.1 M | 76 M | 78.4 M | 76.7 M | 87.4 M | 129 M | 158 M | 214 M | 182 M | 271 M | 292 M | 308 M | 324 M | - | 348 M | 377 M | 360 M | 357 M | 385 M | 60.4 M | 60.5 M | 60.5 M | 60.5 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 10.1 M | 10.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
3.56 M | 3.42 M | 9.57 M | 3.06 M | 3.56 M | 3.62 M | 9.17 M | 8.79 M | 10.4 M | 15.8 M | 17.9 M | 34.6 M | 14.9 M | 4.1 M | 5.09 M | 28.2 M | 27.2 M | 24 M | 24.6 M | 141 M | 333 M | 362 M | 38.4 M | 38.4 M | 38.4 M | 38.4 M | 17.3 M | 17.3 M | 17.3 M | 17.3 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 1.02 M | 1.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
44.4 M | 37.5 M | 35.4 M | 49.8 M | 45.4 M | 48.2 M | 35.4 M | 48.9 M | 80.3 M | 82.8 M | 96.2 M | 119 M | 215 M | 231 M | 249 M | 282 M | - | 311 M | 337 M | 342 M | 346 M | 363 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 3.61 M | 3.61 M | 3.61 M | 3.61 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | -7.22 M | -7.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
35.4 M | 37.5 M | 96.2 M | 49.8 M | 45.4 M | 48.2 M | 35.4 M | 48.9 M | 80.3 M | 82.8 M | 96.2 M | 119 M | 215 M | 231 M | 249 M | 282 M | 285 M | 311 M | 337 M | 342 M | 346 M | 363 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 3.61 M | 3.61 M | 3.61 M | 3.61 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | -50.2 M | -50.2 M | - | - | -27.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of BioNano Genomics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
$ 2.81 | 1.63 % | $ 91.2 K |  USA |
 |
Biodesix
BDSX
|
$ 27.49 | 1.95 % | $ 208 M | USA |
 |
Biomerica
BMRA
|
$ 2.4 | 5.96 % | $ 7 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 11.67 | 5.68 % | $ 123 M |  China |
 |
Bioventus
BVS
|
$ 13.22 | 1.85 % | $ 881 M | USA |
 |
CareDx, Inc
CDNA
|
$ 52.37 | 4.21 % | $ 2.79 B | USA |
 |
Celcuity
CELC
|
$ 83.55 | 0.12 % | $ 3.91 B | USA |
 |
Co-Diagnostics
CODX
|
$ 1.14 | 1.79 % | $ 1.52 M | USA |
 |
Charles River Laboratories International
CRL
|
$ 269.48 | 0.06 % | $ 13.4 B | USA |
 |
Castle Biosciences
CSTL
|
$ 33.22 | 2.74 % | $ 963 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 239.32 | 1.83 % | $ 26.6 B | USA |
 |
Danaher Corporation
DHR
|
$ 202.7 | 1.28 % | $ 144 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 7.1 | 2.31 % | $ 28.3 M |  Israel |
 |
Fulgent Genetics
FLGT
|
$ 20.56 | 0.54 % | $ 633 M | USA |
 |
Guardant Health
GH
|
$ 165.87 | 5.39 % | $ 20.8 B | USA |
 |
ICON Public Limited Company
ICLR
|
$ 169.34 | 0.02 % | $ 13.3 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 509.72 | 0.99 % | $ 41 B | USA |
 |
Illumina
ILMN
|
$ 207.94 | 0.72 % | $ 32.2 B | USA |
 |
IQVIA Holdings
IQV
|
$ 264.81 | 1.16 % | $ 45.5 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Laboratory Corporation of America Holdings
LH
|
$ 314.56 | 0.95 % | $ 26.2 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.27 | 0.02 % | $ 6.77 B | USA |
 |
Medpace Holdings
MEDP
|
$ 591.17 | 0.62 % | $ 17.1 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 287.94 | 1.01 % | $ 26.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 3.74 | 9.36 % | $ 346 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 5.68 | 0.98 % | $ 4.47 M | USA |
 |
NeoGenomics
NEO
|
$ 18.27 | 5.51 % | $ 2.34 B | USA |
 |
Neogen Corporation
NEOG
|
$ 11.87 | 0.72 % | $ 2.58 B | USA |
 |
National Research Corporation
NRC
|
$ 22.14 | 4.83 % | $ 496 M | USA |
 |
Natera
NTRA
|
$ 339.13 | 3.1 % | $ 46.4 B | USA |
 |
OPKO Health
OPK
|
$ 1.55 | 0.38 % | $ 1.16 B | USA |
 |
Pacific Biosciences of California
PACB
|
$ 1.36 | 4.23 % | $ 408 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 25.15 | 2.28 % | $ 23.8 B |  Niderland |
 |
Personalis
PSNL
|
$ 16.3 | 0.52 % | $ 1.45 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Senseonics Holdings
SENS
|
$ 8.88 | 1.95 % | $ 371 M | USA |
 |
Neuronetics
STIM
|
$ 2.89 | 5.61 % | $ 191 M | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 611.62 | 0.3 % | $ 231 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Twist Bioscience Corporation
TWST
|
$ 136.05 | 6.94 % | $ 8.14 B | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.31 | 0.34 % | $ 39 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 407.54 | 1.67 % | $ 24.3 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |